Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/109350
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease
Author: Song, C.
Burgess, S.
Eicher, J.
O'Donnell, C.
Johnson, A.
Huang, J.
Sabater-Lleal, M.
Asselbergs, F.
Tregouet, D.
Shin, S.
Ding, J.
Baumert, J.
Oudot-Mellakh, T.
Folkersen, L.
Smith, N.
Williams, S.
Ikram, M.
Kleber, M.
Becker, D.
Truong, V.
et al.
Citation: Journal of the American Heart Association, 2017; 6(6):e004918-1-e004918-24
Publisher: Wiley Blackwell
Issue Date: 2017
ISSN: 2047-9980
2047-9980
Statement of
Responsibility: 
C. Song … Deborah Lawler … Lyle J. Palmer ... et al. (CHARGE Consortium Hemostatic Factor Working Group; ICBP Consortium; CHARGE Consortium Subclinical Working Group)
Abstract: Background: Plasminogen activator inhibitor type 1 (PAI‐1) plays an essential role in the fibrinolysis system and thrombosis. Population studies have reported that blood PAI‐1 levels are associated with increased risk of coronary heart disease (CHD). However, it is unclear whether the association reflects a causal influence of PAI‐1 on CHD risk. Methods and Results: To evaluate the association between PAI‐1 and CHD, we applied a 3‐step strategy. First, we investigated the observational association between PAI‐1 and CHD incidence using a systematic review based on a literature search for PAI‐1 and CHD studies. Second, we explored the causal association between PAI‐1 and CHD using a Mendelian randomization approach using summary statistics from large genome‐wide association studies. Finally, we explored the causal effect of PAI‐1 on cardiovascular risk factors including metabolic and subclinical atherosclerosis measures. In the systematic meta‐analysis, the highest quantile of blood PAI‐1 level was associated with higher CHD risk comparing with the lowest quantile (odds ratio=2.17; 95% CI: 1.53, 3.07) in an age‐ and sex‐adjusted model. The effect size was reduced in studies using a multivariable‐adjusted model (odds ratio=1.46; 95% CI: 1.13, 1.88). The Mendelian randomization analyses suggested a causal effect of increased PAI‐1 level on CHD risk (odds ratio=1.22 per unit increase of log‐transformed PAI‐1; 95% CI: 1.01, 1.47). In addition, we also detected a causal effect of PAI‐1 on elevating blood glucose and high‐density lipoprotein cholesterol. Conclusions: Our study indicates a causal effect of elevated PAI‐1 level on CHD risk, which may be mediated by glucose dysfunction.
Keywords: Coronary heart disease; genome-wide association study; Mendelian randomization; plasminogen activator inhibitor type 1; single nucleotide polymorphism
Rights: © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
RMID: 0030071737
DOI: 10.1161/JAHA.116.004918
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_109350.pdfPublished Version1.29 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.